Midostaurin (also referred to as PKC412 or Rydapt) is a clinically approved small-molecule inhibitor of multiple protein kinases that is currently used for acute myeloid leukemia (AML) [27,28], mast cell leukemia, and systemic mastocytosis [29,30]. This evidence concerns the gene WEE1 and acute myeloid leukemia.